Free Trial

Neuronetics, Inc. (NASDAQ:STIM) Short Interest Up 39.7% in March

Neuronetics logo with Medical background
Remove Ads

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,780,000 shares, an increase of 39.7% from the February 28th total of 1,990,000 shares. Approximately 10.2% of the company's stock are sold short. Based on an average daily trading volume, of 1,440,000 shares, the short-interest ratio is presently 1.9 days.

Insider Transactions at Neuronetics

In other news, CEO Keith J. Sullivan sold 40,992 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $134,453.76. Following the transaction, the chief executive officer now directly owns 1,283,362 shares in the company, valued at $4,209,427.36. The trade was a 3.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Stephen Furlong sold 14,836 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.28, for a total value of $48,662.08. Following the sale, the chief financial officer now owns 482,572 shares of the company's stock, valued at approximately $1,582,836.16. This represents a 2.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 100,369 shares of company stock valued at $358,929 over the last quarter. Company insiders own 9.80% of the company's stock.

Remove Ads

Institutional Trading of Neuronetics

Several large investors have recently made changes to their positions in STIM. Tradewinds LLC. acquired a new stake in Neuronetics in the 4th quarter worth approximately $32,000. XTX Topco Ltd acquired a new stake in shares of Neuronetics in the fourth quarter worth $49,000. Wealthedge Investment Advisors LLC acquired a new stake in shares of Neuronetics in the fourth quarter worth $57,000. David J Yvars Group grew its stake in Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company's stock valued at $75,000 after buying an additional 14,825 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Neuronetics by 10,954.1% in the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company's stock worth $88,000 after acquiring an additional 54,442 shares during the period. Institutional investors own 53.59% of the company's stock.

Neuronetics Stock Down 8.6 %

NASDAQ:STIM traded down $0.34 during trading hours on Thursday, reaching $3.60. The company's stock had a trading volume of 1,333,427 shares, compared to its average volume of 645,234. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The company has a market cap of $109.25 million, a price-to-earnings ratio of -2.93 and a beta of 1.97. Neuronetics has a one year low of $0.52 and a one year high of $5.92. The business's 50-day moving average is $4.11 and its 200-day moving average is $2.20.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group increased their price objective on Neuronetics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th.

View Our Latest Analysis on Neuronetics

Neuronetics Company Profile

(Get Free Report)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Read More

Should You Invest $1,000 in Neuronetics Right Now?

Before you consider Neuronetics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neuronetics wasn't on the list.

While Neuronetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

3 Stocks to Buy on the Dip—and 3 to Dump Fast
Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads